Clinical Trial Update: A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL [EARLY_Phase 1]

View source ↗

Summary

An early-phase study of GC022 CAR-T cell immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia, sponsored by Hebei Yanda Ludaopei Hospita…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• GC022 CAR-T cell immunotherapy

Snippet

Sponsor: Hebei Yanda Ludaopei Hospital | Conditions: B-cell Acute Lymphoblastic Leukemia | EARLY_Phase 1 | Status: UNKNOWN